Chemotherapy for advanced epithelial ovarian cancer.
In the past decade there have been significant improvements in chemotherapy for advanced ovarian cancer. Platinum-based chemotherapy has improved response rates and, to a lesser degree, prolonged survival. Taxol and its combination with platinum drugs holds the promise for even further improvements in survival. Clinical trials are evaluating issues such as dose-intensity, new combinations, and drug resistance.
Ozols
R F
RF
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents